戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1      Bilateral intra-hippocampal infusion of ALLO (0.1 microg/side) was anticonvulsant, increasing th
2 rms of lithocholic acid (LCA): iso-, 3-oxo-, allo-, 3-oxoallo- and isoallolithocholic acid.
3                                              ALLO (3alpha5alpha and 3alpha5beta isomers) binds with h
4 osphates accepted by E(p) to include alpha-d-allo-, alpha-d-altro-, and alpha-d-talopyranosyl phospha
5 allows a rationalization of the inability of allo-, altro-, and glucopyranosyl-based oligonucleotides
6  We identified 81 nocardiosis episodes in 74 allo- and 7 auto-HCT recipients.
7 s concept due to interspecies hybridization, allo- and auto-polyploidy, and phenotypic plasticity.
8 ts died of transplant-related toxicity after allo- and auto-SCT, respectively.
9 lls (PCs) are the major source of pathogenic allo- and autoantibodies and have historically demonstra
10 of antibodies against type II collagen (both allo- and autoantibodies) were measured.
11 were significantly elevated in patients with allo- and autoantibody-mediated thrombocytopenias compar
12                            In contrast, both allo- and autograft recipients had glucagon responses to
13 ) through chemokine signaling could mitigate allo- and autoimmune attack on transplanted beta-cells,
14 n are emerging therapeutic options for these allo- and autoimmune conditions.
15                   CD177 presents antigens in allo- and autoimmune diseases on the neutrophil surface.
16 as a potent cellular therapy to control both allo- and autoimmune diseases.
17 opment of immunologic strategies to curb the allo- and autoimmune processes in beta-cell transplant r
18 n monocytes and macrophages participating in allo- and autoimmune reactions, including the perivascul
19 ss has been made in clarifying mechanisms of allo- and autoimmune responses to FVIII and in suppressi
20 that tolerance strategies should target both allo- and autoimmune responses to prevent this process.
21  that lung allograft rejection involves both allo- and autoimmune responses, and graft destruction th
22    B cells participate in the priming of the allo- and autoimmune responses, and their depletion can
23 n down-modulate T cell response and suppress allo- and autoimmune responses.
24 aftment of encapsulated murine beta-cells in allo- and autoimmune settings.
25 ransplants seems unlikely to be explained by allo- and autoimmune-mediated mechanisms alone and in a
26 erapeutic use to simultaneously control both allo- and autoimmunity in islet transplantation.
27 nclude that allogeneic HSC transplants block allo- and autoimmunity, despite residual host T-cell pre
28  Because T(reg) dysfunction can lead to both allo- and autoimmunity, there is interest in correcting
29 with no effect on IL-10 production, for both allo- and autologous T cell proliferation.
30 ium borohydride and then deprotected to give allo- and epi-inositol in good yield that confirmed the
31 and immunostimulatory capacity in presenting allo- and islet-associated antigens by NF-kappaB ODN DC
32 P-10) were expressed at equivalent levels in allo- and isografts for 2-4 days posttransplant and then
33 unctional differences by MSC in responses to allo- and recall Ags, we examined whether MSC could exer
34 no difference in precursor frequency between allo- and xeno-reactive CD4+ CD25+ FoxP3 high cells.
35                     Further investigation on allo- and xenoantibody cross-reactivity is required.
36 ic surface phenotype and efficiently present allo- and xenoantigens to allogeneic T cells after co-cu
37 nfluences endothelial-mediated activation of allo- and xenogeneic immune cells.
38  precursor and primary foetal grafts in both allo- and xenograft environments using several labelling
39 ons such as inflammation, chronic arthritis, allo- and xenograft rejection.
40                            Cardiac and renal allo- and xenografts can become naturally resistant to v
41  and long-term functional viability of islet allo- and xenografts in immune-competent recipients with
42 e in the immune response against solid organ allo- and xenografts.
43                                              Allo- and xenoreactive IgG and IgM, measured by T cell a
44   The expansion and precursor frequencies of allo- and xenoreactive Tregs were assessed by labeling w
45                                         Skin allo- and xenotransplantation are the standard treatment
46 e use of baboons as a model for the study of allo- and xenotransplantation has become increasingly im
47 ideration when analyzing immune responses to allo- and xenotransplantation in baboons.
48 n, will offer insight into new therapies for allo- and xenotransplantation.
49 icant barrier to successful outcomes in both allo- and xenotransplantation.
50 with alpha-d-galacto-, alpha-d-talo-, beta-d-allo-, and alpha-d-altropyranoside stereochemistry, from
51                The novel, recently described allo (antigen)-specific CD154+T cells were evaluated for
52                         The concentration of ALLO ( approximately 40 fmol/ml in each CSF fraction of
53 glycoprotein complex is a favored target for allo-, auto-, and drug-dependent antibodies associated w
54 SCID into hyperglycemic NOD), and in a mixed allo-/autoimmune setting (BALB/c into hyperglycemic NOD)
55 ring analogues in descending order was KAC > ALLO > MAC, with increments similar to the biphenyl comp
56                    We adoptively transferred allo-(H-2d)-reactive Tcl or Tc2 cells from H-2b mice int
57 eic hematopoietic stem cell transplantation (allo- HSCT) t(8;21) (q22;q22) acute myeloid leukemia pat
58 ses novel insights into mechanisms of (auto-/allo-)immune diseases and more rationally designed antib
59 t the classic theory of concentric mammalian allo-, meso-, and neocortex domains.
60                          Whereas allogeneic (allo-)MSCs are immunoevasive, the capacity of CSCs to si
61 eminent, with "other" inositols (cis-, epi-, allo-, muco-, neo-, L-chiro-, D-chiro-, and scyllo-) and
62 rty-seven patients were randomized to either allo- or auto-hMSCs in a 1:1 ratio.
63 all survival at 3 years was 57% vs 70% after allo- or auto-SCT, without significant differences betwe
64 let destruction is most frequently caused by allo- or autoantibodies via Fcgamma receptor-dependent p
65 ial to inhibit undesired immune responses to allo- or autoantigens.
66 for those that could mount the most vigorous allo- or autoimmune responses, or perhaps become toleran
67  two classes and whether WGD results from an allo- or autopolyploid event is inconsistent with recent
68 cies based on defined meiotic parameters for allo- or autotetraploid species with a gametophytic S-Z
69 ain expected values for for diploid and for (allo- or autotetraploidy SI grasses.
70 s donors and recipients for orthotopic liver allo- or iso-graft transplants.
71 suppressive agent for reversing the onset of allo- or possibly autoimmune attacks against pancreatic
72 occur physiologically as a result of chronic allo- or self-antigen stimulation.
73 ciated peptides that have been identified as allo- or xenoantigens is consistent with this hypothesis
74 n CD8+ T cells elicit a vigorous response to allo- or xenogeneic MHC class I molecules.
75  a given MHC-bound peptide to the responding allo- or xenoreactive T cell repertoire is not clear.
76 , we show that the deletion of Fas or B2m in allo- T cells increases their survival in immunocompeten